Monoclonal antibodies (mAbs) still occupy a major position in the push for precision-based cancer therapy by providing targeted, highly efficient modality for treatment. The launch of next generation mAb products represents a major advance in the field of oncology that incorporates cutting-edge engineering to improve specificity, potency, and safety of new agents. These next generation mAbs will interfere with critical oncogenic avenues, recruit immune effector cells, and deliver a cytotoxic payload directly to the tumor site. Additionally, innovations such as bispecific antibodies, Fc-engineered drugs, and antibody-drug conjugates represent a new class of mAbs that will set new standards of care for numerous cancer types.

This session at the Cancer Research and Development Conference 2026 will present clinical launches and developments in the science of monoclonal antibody development and application. Experts will discuss therapeutic benefits, regulatory pathways and combination strategies that optimized patient outcomes. Join us to discuss how the next generation of monoclonal antibodies will change the arena of cancer therapy, introducing a new layer of targeted precision and improved survival for patients around the globe.